The test is specific and sensitive (detection of 10 cancer cells/ml blood), and only minimally invasive. Positivity is statistically correlated to high grade neuroendocrine carcinomas and to a poor prognosis with a 3-fold higher lethal risk. The test now needs to be assessed for its usefulness...
So how much might treatment cost you? It depends on yourinsurance plan, what type and stage of cancer you have, where you live, and more. But a couple of studies shed some light on possible expenses. One study looked at costs allowed by insurance companies for breast cancer surgery, chemo...
This may be a relief. However, there is also the frustrating fact that even if a woman has a negative genetic test, she is still at higher risk for breast cancer than the general population due to the risk factor of having multiple family members with breast cancer. Another possibility with...
Objectives: Genetic mutations in breast cancer susceptibility genes BRCA1/2 are associated with an increased risk of breast/ovarian cancers. Cost-effective preventive measures are available for women who test positive. The objective of this study was to determine at what risk of mutation it is cos...
A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer. Value Health. 2017;20(4):547-555. doi:10.1016/j.jval.2017.01.006Crossref 60. Havrilesky LJ, Broadwater G, Davis DM, et al. Determination of quality of life-...
A new study by a UCLA researcher in collaboration with colleagues at Harvard and University of Texas Southwestern has found that a genomic test widely used to help determine whether women with a common form of breast cancer should undergo radiation is not cost effective. The Oncotype Dx DCIS tes...
To evaluate the cost-effectiveness of BRCA testing in women with breast cancer, and cascade testing in family members of BRCA mutation carriers. A cost-effectiveness analysis was conducted using a cohort Markov model from a health-payer perspective. The
The probability according to which FEC 50 is strictly dominated by FEC 100 was 0.15. The clinical benefit of FEC 100 generates a negligible cost increase when compared with FEC 50. 展开 关键词: adjuvant breast cancer cost cost-effectiveness FEC ...
Most life insurance companies that responded to the survey would offer a standard premium in scenario 1 (unremarkable except breast cancer in the mother diagnosed at age 35). The lifetime relative risk of developing breast cancer for the applicant in scenario 1 is 5.7 (2.7 to 11.8).2 Using ...
Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UK Brown R E,Hutton J,Burrell A.Cost effectiveness of treatment options in advanced breast cancer in the UK.Pharmacoeconomics. 2001... DRE Brown,J Hutton,A Burrell - 《Pharmacoeconomics》 被引量: 249发表: 2001年 The ...